Revenue from Contracts with Customers Schedule of Disaggregated Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 106,732,000	$ 114,905,000	$ 86,489,000
Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	21,441,000	20,839,000	24,229,000
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	43,847,000	38,311,000	37,545,000
In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	9,445,000	6,745,000	4,168,000
Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	74,733,000	65,895,000	65,942,000
Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	8,790,000	6,115,000	3,192,000
Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	83,523,000	72,010,000	69,134,000
Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	23,209,000	42,895,000	17,355,000
Americas
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	74,137,000	86,099,000	60,330,000
Americas | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	12,033,000	10,556,000	12,086,000
Americas | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	29,653,000	25,583,000	27,015,000
Americas | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	3,014,000	2,473,000	1,517,000
Americas | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	44,700,000	38,612,000	40,618,000
Americas | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,228,000	4,592,000	2,357,000
Americas | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	50,928,000	43,204,000	42,975,000
Americas | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	23,209,000	42,895,000	17,355,000
Europe and Middle East
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	25,715,000	21,791,000	18,497,000
Europe and Middle East | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,677,000	6,561,000	7,900,000
Europe and Middle East | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	10,847,000	9,934,000	7,481,000
Europe and Middle East | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,094,000	3,982,000	2,476,000
Europe and Middle East | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	23,618,000	20,477,000	17,857,000
Europe and Middle East | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	2,097,000	1,314,000	640,000
Europe and Middle East | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	25,715,000	21,791,000	18,497,000
Europe and Middle East | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	0	0	0
Asia Pacific
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,880,000	7,015,000	7,662,000
Asia Pacific | Instruments
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	2,731,000	3,722,000	4,243,000
Asia Pacific | Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	3,347,000	2,794,000	3,049,000
Asia Pacific | In Vitro Diagnostic Kits
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	337,000	290,000	175,000
Asia Pacific | Total product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,415,000	6,806,000	7,467,000
Asia Pacific | Service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	465,000	209,000	195,000
Asia Pacific | Total product and service revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	6,880,000	7,015,000	7,662,000
Asia Pacific | Collaboration
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 0	$ 0	$ 0